Grifols Evaluates Potential US IPO for Biopharma Business

martes, 24 de marzo de 2026, 5:49 pm ET1 min de lectura
GRFS--

Grifols, a Spanish pharmaceutical company, is considering an IPO of its US biopharma business as part of its self-sufficiency program. While there is no guarantee an IPO will happen, the company must go through regulatory and legal requirements, internal approvals, and favorable market conditions.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios